Wanbury
229.85
-2.40(-1.03%)
Market Cap₹763.60 Cr
PE Ratio17.52
IndustryHealthcare
Company Performance:
1D-1.03%
1M-9.72%
6M-12.76%
1Y-7.09%
5Y+584.08%
View Company Insightsright
More news about Wanbury
23Apr 25
Wanbury Limited Embarks on Digital Transformation with SAP S/4 HANA Implementation
Wanbury Limited, a pharmaceutical company, has announced the implementation of SAP S/4 HANA Private Cloud Platform to enhance its digital capabilities. The system aims to improve processes in finance, sales, production, quality, material management, and compliance. Partnering with Deloitte Consulting, Wanbury expects this move to drive operational excellence, foster innovation, and support sustainable growth. The implementation is scheduled for the current financial year.
06Mar 25
Wanbury Limited Slashes Interest Costs with ₹175 Crore Debt Refinancing
Wanbury Limited has successfully refinanced ₹175 crore of existing debt through Emerging India Credit Opportunities Fund II. The new deal features a 12.5% per annum interest rate, down from 21% on previous NCDs, with a 5-year tenure and 9-month moratorium. The refinancing includes repurchase of ₹95 crore NCDs and refinancing of ₹150 crore existing debt. This move is expected to significantly reduce Wanbury's interest burden and improve its financial health.
Wanbury
229.85
-2.40
(-1.03%)
1 Year Returns:-7.09%
Industry Peers
Sun Pharmaceutical
1,679.10
(+1.21%)
Divis Laboratories
6,621.50
(+0.32%)
Cipla
1,577.60
(+0.52%)
Torrent Pharmaceuticals
3,584.30
(+1.43%)
Dr Reddys Laboratories
1,255.90
(+1.27%)
Mankind Pharma
2,476.60
(+0.87%)
Zydus Life Science
987.65
(+0.31%)
Lupin
1,940.00
(-0.57%)
Alkem Laboratories
5,581.50
(+1.04%)
Aurobindo Pharma
1,101.00
(-0.48%)